Literature DB >> 31175972

Characterization of oral candidiasis and the Candida species profile in patients with oral mucosal diseases.

Lijun Hu1, Chun He2, Chen Zhao1, Xuejie Chen1, Hong Hua1, Zhimin Yan3.   

Abstract

BACKGROUND: The oral mucosa is likely to be compromised by acquired systemic disease. There are no data available on the prevalence of oral candidiasis and the species distribution among patients with oral mucosal diseases. Therefore, it is necessary to conduct a study assessing the characterization of oral candidiasis and the species profiles in such patients.
METHODS: Over a period of four consecutive years, patients with oral mucosal diseases were screened for oral candidiasis by a combination of clinical presentation and laboratory findings (smear test and Candida cultures). In addition, Candida species were isolated and identified for further analysis.
RESULTS: In total, 9769 (6.09%) of the 160,357 patients screened were diagnosed with oral candidiasis on the basis of both clinical manifestations and laboratory testing. The ratio of females to males was 1:0.61, and females had higher overall infection rates than males in all age subgroups. Patients with HIV infection, anaemia-related stomatitis, Sjögren's syndrome/xerostomia, pemphigoid, and radiation-induced stomatitis were highly susceptible to oral candidiasis. Of the 11,161 isolated Candida strains, C. albicans remained the most common species (75.37%), followed by C. tropicalis (6.06%), C. krusei (2.79%), and C. glabrata (2.02%). Surprisingly, both the proportion and the number of C. glabrata isolates increased dramatically over the 4 consecutive years.
CONCLUSIONS: In this large-scale population-based study, the features of oral candidiasis prevalence and the species profile among patients with oral mucosal diseases were summarized. The information gleaned will enhance the understanding of and improve management strategies for oral candidiasis and the underlying systemic and oral conditions.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Candida glabrata; Candida species; Oral candidiasis; Oral mucosal diseases

Mesh:

Substances:

Year:  2019        PMID: 31175972     DOI: 10.1016/j.micpath.2019.103575

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  12 in total

1.  Candida albicans CHK1 gene from two-component system is essential for its pathogenicity in oral candidiasis.

Authors:  Yujie Zhou; Lei Cheng; Binyou Liao; Yangyang Shi; Yulong Niu; Chengguang Zhu; Xingchen Ye; Xuedong Zhou; Biao Ren
Journal:  Appl Microbiol Biotechnol       Date:  2021-02-26       Impact factor: 4.813

2.  Influence of oral biofilm index, caries experience, and laboratory markers of disease progression on the oral carriage of Candida in HIV-infected and non-infected children: a cross-sectional study.

Authors:  Edja Maria Melo de Brito Costa; Carolina Medeiros de Almeida Maia; Priscilla Guimarães Silva Vasconcelos; Maristela Barbosa Portela; Caroliny Mello Barboza; Abel Silveira Cardoso; Rosangela Maria de Araújo Soares; André Luis Souza Dos Santos
Journal:  Braz J Microbiol       Date:  2022-10-13       Impact factor: 2.214

3.  Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab).

Authors:  Bruna Lavinas Sayed Picciani; Arkadiusz Dziedzic; Juliana Tristão Werneck; Marcello Alves Marinho; Thaylla Núñez Amin Dick; Nara Regina Quintanilha; Eliane Pedra Dias
Journal:  BMC Oral Health       Date:  2021-06-08       Impact factor: 2.757

4.  Influence of Incubation Time on Ortho-Toluidine Blue Mediated Antimicrobial Photodynamic Therapy Directed against Selected Candida Strains-An In Vitro Study.

Authors:  Rafał Wiench; Joanna Nowicka; Magdalena Pajączkowska; Piotr Kuropka; Dariusz Skaba; Anna Kruczek-Kazibudzka; Anna Kuśka-Kiełbratowska; Kinga Grzech-Leśniak
Journal:  Int J Mol Sci       Date:  2021-10-11       Impact factor: 5.923

5.  In vitro and in vivo anti-Candida activity of citral in combination with fluconazole.

Authors:  Katherine Miranda-Cadena; Cristina Marcos-Arias; Aitzol Perez-Rodriguez; Iván Cabello-Beitia; Estibaliz Mateo; Elena Sevillano; Lucila Madariaga; Guillermo Quindós; Elena Eraso
Journal:  J Oral Microbiol       Date:  2022-03-02       Impact factor: 5.474

6.  Sodium houttuyfonate enhances the mono-therapy of fluconazole on oropharyngeal candidiasis (OPC) through HIF-1α/IL-17 axis by inhibiting cAMP mediated filamentation in Candida albicans-Candida glabrata dual biofilms.

Authors:  Mengli Chen; Ting Cheng; Chen Xu; Min Pan; Jiadi Wu; Tianming Wang; Daqiang Wu; Guiming Yan; Changzhong Wang; Jing Shao
Journal:  Virulence       Date:  2022-12       Impact factor: 5.882

7.  The Catestatin-Derived Peptides Are New Actors to Fight the Development of Oral Candidosis.

Authors:  Davide Mancino; Naji Kharouf; Francesco Scavello; Sophie Hellé; Fouad Salloum-Yared; Angela Mutschler; Eric Mathieu; Philippe Lavalle; Marie-Hélène Metz-Boutigue; Youssef Haïkel
Journal:  Int J Mol Sci       Date:  2022-02-13       Impact factor: 5.923

8.  Antifungal susceptibility of Candida species to copper oxide nanoparticles on polycaprolactone fibers (PCL-CuONPs).

Authors:  Antonio Muñoz-Escobar; Simón Yobanny Reyes-López
Journal:  PLoS One       Date:  2020-02-24       Impact factor: 3.240

9.  In Vitro and In Vivo Anti-Candida spp. Activity of Plant-Derived Products.

Authors:  Reginaldo Dos Santos Pedroso; Brenda Lorena Balbino; Géssica Andrade; Maria Cecilia Pereira Sacardo Dias; Tavane Aparecida Alvarenga; Rita Cássia Nascimento Pedroso; Letícia Pereira Pimenta; Rodrigo Lucarini; Patrícia Mendonça Pauletti; Ana Helena Januário; Marco Túlio Menezes Carvalho; Mayker Lazaro Dantas Miranda; Regina Helena Pires
Journal:  Plants (Basel)       Date:  2019-11-11

Review 10.  Efficacy of Toluidine Blue-Mediated Antimicrobial Photodynamic Therapy on Candida spp. A Systematic Review.

Authors:  Rafał Wiench; Dariusz Skaba; Jacek Matys; Kinga Grzech-Leśniak
Journal:  Antibiotics (Basel)       Date:  2021-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.